Risk-Based Selection of Environmental Classifications for Biopharmaceutical Operations

References

1. 1.↵
   European Commission, EudraLex—The Rules Governing Medicinal Products in the European Union, Volume 4: Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 2 Manufacture of Biological Medicinal Products for Human Use. European Commission: Brussels, 2018.
2. 2.↵
   1. Blake J.,
   2. Estape D.,
   3. Green K.,
   4. Iyer K. R.,
   5. Johnson J.,
   6. Mcduff P.,
   7. Pelletier M.,
   8. Powell A.,
   9. Probst S.,
   10. Smock P.,
   11. Payne R.,
   12. Corbidge T.

   BPOG Response to Annex 2 PDA J. Pharm. Sci. Technol. 2016, 70 (3), 300–311.

   OpenUrlFREE Full Text
3. 3.↵
   1. Probst S.,
   2. Pancorbo J.,
   3. Pelletier M.,
   4. Afanado N. L.,
   5. Iyer K. R.,
   6. Johnson J. C.,
   7. Corbidge T.

   Data-Driven Equipment and Facility Design Case Study: Functional Closure of a Hybrid Connection System, 2018. BioPhorum Web site. https://www.biophorum.com/download/data-driven-equipment-and-facility-design-case-study/ (accessed June 10, 2021).
4. 4.↵
   1. Pelletier M.

   Death to Cleanrooms in Biopharmaceutical Manufacturing, PAP-Q1-18-CL-006, 2018. Pharma’s Almanac Web site. https://www.pharmasalmanac.com/articles/death-to-cleanrooms-in-biopharmaceutical-manufacturing (accessed June 10, 2021).
5. 5.↵
   International Society for Pharmaceutical Engineering, ISPE Baseline Guide Volume 6: Biopharmaceutical Manufacturing Facilities. ISPE: Tampa, FL, 2013.
6. 6.↵
   1. Estapé D.,
   2. Walker A. L.,
   3. Orichowskyj S. T.,
   4. Vega H.,
   5. Pratt D. J.

   Proof of Closure: Life Cycle of Closed Systems. Pharm. Eng. 2017, 37 (5), 51–59.

   OpenUrl
7. 7.↵
   1. Whyte W.,
   2. Eaton T.

   A Cleanroom Contamination Control System. Eur. J. Parenter. Pharm. Sci. 2002, 7 (2), 55–61.

   OpenUrl
8. 8.↵
   1. Whyte W.,
   2. Eaton T.

   Microbiological Contamination Models for Use in Risk Assessment during Pharmaceutical Production. Eur. J. Parenter. Pharm. Sci. 2004, 9 (1), 11–15.

   OpenUrl
9. 9.↵
   1. Whyte W.,
   2. Eaton T.

   Microbial Risk Assessment in Pharmaceutical Cleanrooms. Eur. J. Parenter. Pharm. Sci. 2004, 9 (1), 16–23.

   OpenUrl
10. 10.↵
    1. Bain D.,
    2. Hardy D.,
    3. Bell B. L.,
    4. Forng R. Y.,
    5. Knight M.,
    6. Bawa A.,
    7. Ramsey S.,
    8. Arbesser-Rastburg C.,
    9. Paul M.,
    10. Ton C.,
    11. Leira F.,
    12. Roman C.,
    13. McFarland K.,
    14. Phillips D.,
    15. Stuckey J.,
    16. Bauer C.,
    17. Calvo A. J.

    Microbial Monitoring for Biological Drug Substance Manufacturing: An Industry Perspective. PDA J. Pharm. Sci. Technol. 2015, 69 (3), 451–456.

    OpenUrlFREE Full Text
11. 11.↵
    International Conference for Harmonisation, Quality Guideline Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients. ICH: Geneva, 2000.
12. 12.↵
    European Commission, EudraLex—The Rules Governing Medicinal Products in the European Union, Volume 4: Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 1: Manufacture of Sterile Medicinal Products. European Commission: Brussels, 2008.
13. 13.↵
    Pharmaceutical Inspection Convention/Cooperation Scheme, Guide to Good Manufacturing Practice for Medicinal Products—Annex II: Manufacture of Biological Medicinal Substances and Products for Human Use. PIC/S: Geneva, 2017.
14. 14.↵
    1. Bourdichon F.,
    2. Ben Cheikh M. H.

    New Food [Online] 2010, (5). https://www.newfoodmagazine.com/article/3102/predictive-modelling-of-microbial-behaviour-in-foods-an-industrial-perspective-and-applications/ (accessed June 10, 2021).
15. 15.↵
    1. Monod J.

    The Growth of Bacterial Cultures. Annu. Rev. Microbiol. 1949, 3 (1), 371–394.

    OpenUrlCrossRefWeb of Science